Aduro Biotech Inc., of Berkeley, Calif., said that during the upcoming American Association for Cancer Research meeting in New Orleans, its chief scientific officer, Thomas Dubensky will present an overview of a planned phase I trial to evaluate the safety, tolerability and possible anti-tumor activity of ADU-S100 given by intratumoral injection to patients with advanced cutaneously accessible solid tumors or lymphomas.